EP194: Why Capturing Patient Reported Outcomes Makes a Whole Lot of Sense, With Dyan Bryson of Inspired Health Strategies
August 16, 2018
194
31:06

EP194: Why Capturing Patient Reported Outcomes Makes a Whole Lot of Sense, With Dyan Bryson of Inspired Health Strategies

You can learn more at www.inspiredhealthstrategies.com.

Dyan is the owner of a patient-focused consultancy, Inspired Health Strategies, LLC (IHS). After spending 20+ years in Big Pharma in traditional sales and marketing roles, in 2007 Dyan began working as a contractor with Sanofi. She was brought in to develop a multi-cultural marketing initiative and Dyan had little hope of making much of an impact until she realized that Sanofi was serious as evidenced by their commitment to a hefty budget and an enterprise-wide effort. She knew that, given her past experience combined with a non-traditional approach to market research, she could help Sanofi develop a groundbreaking program. What was developed was a program that incorporated the patient’s ecosystem into a branded and non-branded initiative that resulted in documented behavior change and significant contribution to the bottom-line. The Community Health Partnership (CHP) changed her brain – she now understood the opportunity the industry was missing by not understanding the value of the patient.

Since that Sanofi initiative Dyan has been an evangelist for patient engagement. But after years of trying to push the industry in this patient-focused direction she was ready to give up…until she attended the March 19, 2018 FDA meeting regarding the Patient-Focused Drug Development (PFDD) initiative. The FDA was going to actually issue guidance that echoes Dyan’s mantra – that patients should be involved in drug development, in a meaningful way, from pre-Investigative New Drug Application (IND) through commercial. This has rejuvenated Dyan’s efforts as she watches and helps the industry sort out how to comply with this guidance. Compliance will demand a change in thinking in the industry and will produce great results for patients.

Dyan’s efforts have been recognized by her being included in the PharmaVoice 100 Innovators in Life Sciences. Dyan has been published in several industry journals including Pharmaceutical Commerce and The Journal of Patient Adherence and is a frequent speaker at industry meetings.

You can learn more about PFDD and see case studies on the work of IHS at Dyan’s website www.inspiredhealthstrategies.com, follow Dyan @InspiredHealth_


00:40 Patient Reported Outcomes, PRO.
01:30 Are patient reported outcomes unscientific?
02:20 Learning to accept the validity of PRO data for what it is.
02:55 Patient-Focused Drug Development - PFDD.
04:10 Closing the loop with patients.
04:55 “It’s hard enough to get people to participate in a clinical trial without making things tough for them.”
10:20 “We’re starting to focus more on real world, in real time.”
13:20 Clinical Outcomes vs Quality of Life Outcomes
18:50 EP157 with Dr Ethan Basch
22:40 “We don’t always know everything.”
25:50 Trying to improve patient adherence.
26:55 Why focusing on behavior increases patient engagement.
27:15 “It’s about engagement.”
30:35 You can learn more at www.inspiredhealthstrategies.com.

healthcare,patient outcomes,inspired health strategies,clinical outcomes vs quality of life outcomes,
|
|

Episode Support Provided By

Special Thanks to Our 2026 Sustaining Monthly Donors

Marilyn Bartlett, Kimberly Carleson, Dylan Yahn, Benjamin Light, Matt McQuide, Ann Kempski, Spencer Allen, Scott Tromanhauser, 
Steven Elkins, Matthew Bunte, and Lori Smith.

Recent Episodes

EP533: Level Funding Is Self-funding: 5 Avoidable Contract Risks, With Frank Pennachio
Relentless Health ValueOctober 14, 2026
533
37:1334.07 MB

EP533: Level Funding Is Self-funding: 5 Avoidable Contract Risks, With Frank Pennachio

Hello, all you Relentless Tribe members. Thanks for hanging with me today to talk about a bunch of things. One of them being what exactly are level-funded plans, and what are the upsides, and then what are the risks? Because here's the thing. I was talking to an employer the other day, an employer w...

EP532: Why Avoidable ER Visits Aren't the Real Cost Problem: Revisiting Our 2016 Interview With HHS Nominee Chris Klomp
Relentless Health ValueOctober 07, 2026
532
37:2034.17 MB

EP532: Why Avoidable ER Visits Aren't the Real Cost Problem: Revisiting Our 2016 Interview With HHS Nominee Chris Klomp

Listen on Your Favorite App Today we are dipping into the archives for an essential replay from 2016, one decade ago, featuring Chris Klomp back when he served as CEO of a company called Collective Medical. With the nomination of Chris Klomp to serve as deputy secretary of the Department of Health a...

EP531: Slaying the Three-Headed Monster of Health Plan Networks, With Evan Anderson
Relentless Health ValueSeptember 30, 2026
531
38:0634.88 MB

EP531: Slaying the Three-Headed Monster of Health Plan Networks, With Evan Anderson

Listen on Your Favorite App Today, Evan Anderson and I are talking about carrier networks, how they started, how it's going. Because irrespective of whatever the plan was at the very beginning, any given network, especially talking about the big status quo networks, has evolved into what I'll call a...

EP530: A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh
Relentless Health ValueSeptember 23, 2026
530
37:4534.56 MB

EP530: A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh

Listen on Your Favorite App Hello, all you Relentless Tribe members. Thanks for hanging with me this week. When a self-insured plan sponsor sees an infusion claim hit their high-cost case report, and a lot of these infusions are really expensive, so many of them hit the high-cost claim report. For a...

EP529: How Stark Law, Stipends, and Noncompetes Drive Hospital Consolidation, With Eric Bricker, MD
Relentless Health ValueSeptember 16, 2026
529
39:2936.14 MB

EP529: How Stark Law, Stipends, and Noncompetes Drive Hospital Consolidation, With Eric Bricker, MD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Hey, thanks for being here with me every week, some of you every single Thursday. Give yourself a little round of applause, maybe silently and in your own head, depending on where you are. But yeah, you matter. You being here matte...

EP528: The Current State of Primary Care—Inevitable or Fixable? Will It Be Private Equity to the Rescue? With Yashaswini Singh, PhD
Relentless Health ValueSeptember 09, 2026
528
38:4935.53 MB

EP528: The Current State of Primary Care—Inevitable or Fixable? Will It Be Private Equity to the Rescue? With Yashaswini Singh, PhD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Here's the backstory for this episode. Remember episode 519 with Lisa Rosenbaum, MD, where we played a high-stakes kind of game show called "Is the Current State of Primary Care an Absolute Inevitability, or Is It a Needless, Subop...

EP526: Generic Compliance Ratios, Pass-Through Contracts, and Other Pharmacy Plumbing, With Mark Cuban and Cora Opsahl
Relentless Health ValueAugust 26, 2026
526
20:1119.06 MB

EP526: Generic Compliance Ratios, Pass-Through Contracts, and Other Pharmacy Plumbing, With Mark Cuban and Cora Opsahl

Listen on Your Favorite App Hello, all you Relentless Tribe members. If you have listened to this show for any length of time, you know one of our favorite truths around here, which is where there's mystery, there's margin. But today, we aren't just here to point out the mystery. We're here to look ...

Listen and Follow

Sponsored by Aventria Health Group
©2026 BD Bridges LLC. All Rights Reserved.